Claims
- 1. A method for the delivery of a substantially water insoluble pharmacologically active agent to a subject in need thereof, said method comprising combining said agent with an effective amount of a pharmaceutically acceptable carrier which is substantially free of cremophor, and administering an effective amount of said combination to said subject.
- 2. A method according to claim 1 wherein said agent is paclitaxel.
- 3. A method according to claim 1 wherein said pharmaceutically acceptable carrier is albumin.
- 4. A method according to claim 1 wherein said combination is administered by oral, intravenous, subcutaneous, intraperitoneal, intrathecal, intramuscular, intracranial, inhalational, topical, transdermal, rectal, or pessary route of administration.
- 5. A method to reduce entrapment of a substantially water insoluble pharmacologically active agent in vehicle employed for delivery thereof, said method comprising combining said agent with a pharmaceutically acceptable carrier which is substantially free of cremophor prior to delivery thereof.
- 6. A method according to claim 5 wherein said agent is paclitaxel.
- 7. A method according to claim 5 wherein said pharmaceutically acceptable carrier has substantially lower affinity for said agent than does cremophor.
- 8. A method to reduce entrapment of a substantially water insoluble pharmacologically active agent in vehicle employed for delivery thereof, said method comprising employing a pharmaceutically acceptable carrier which is substantially free of cremophor in aqueous media as the vehicle for delivery of said agent.
- 9. A method to prolong exposure of a subject to a substantially water insoluble pharmacologically active agent upon administration thereof to a subject in need thereof, said method comprising combining said agent with a pharmaceutically acceptable carrier which is substantially free of cremophor prior to delivery thereof.
- 10. A method to facilitate transport of a substantially water insoluble pharmacologically active agent across cell membranes upon administration thereof to a subject in need thereof, said method comprising combining said agent with a pharmaceutically acceptable carrier which is substantially free of cremophor prior to delivery thereof.
- 11. A method to facilitate transport of a substantially water insoluble pharmacologically active agent into the cellular compartment upon administration thereof to a subject in need thereof, said method comprising combining said agent with a pharmaceutically acceptable carrier which is substantially free of cremophor prior to delivery thereof.
- 12. A formulation comprising a substantially water insoluble pharmacologically active agent and a pharmaceutically acceptable carrier which is substantially free of cremophor, wherein said formulation provides a higher concentration of said agent in the cellular compartment than a formulation of the same agent with cremophor.
- 13. A formulation comprising a substantially water insoluble pharmacologically active agent and a pharmaceutically acceptable carrier which is substantially free of cremophor, wherein said formulation provides increased intra-cellular availability of said agent relative to a formulation of the same agent with cremophor.
- 14. A formulation comprising a substantially water insoluble pharmacologically active agent and a pharmaceutically acceptable carrier which is substantially free of cremophor, wherein said formulation provides prolonged activity of said agent relative to a formulation of the same agent with cremophor.
- 15. A formulation comprising a substantially water insoluble pharmacologically active agent and a pharmaceutically acceptable carrier which is substantially free of cremophor, wherein said agent has a longer half life in said formulation relative to the half life of said agent in a formulation with cremophor.
- 16. A formulation comprising a substantially water insoluble pharmacologically active agent and a pharmaceutically acceptable carrier which is substantially free of cremophor, wherein said formulation enhances delivery of said agent to tissue, relative to a formulation of the same agent with cremophor.
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. Ser. No. 08/485,448, filed Jun. 7, 1995, now pending, which is, in turn, a continuation-in-part of U.S. Ser. No. 08/200,235, now issued as U.S. Pat. No. 5,498,421, which is, in turn, a continuation-in-part of U.S. Ser. No. 08/023,698, filed Feb. 22, 1993, now issued as U.S. Pat. No. 5,439,686, and U.S. Ser. No. 08/035,150, filed Mar. 26, 1993, now issued as U.S. Pat. No. 5,362,478, the contents of each of which are hereby incorporated by reference in their entirety.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08926155 |
Sep 1997 |
US |
Child |
09628388 |
Aug 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09628388 |
Aug 2000 |
US |
Child |
10146078 |
May 2002 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
08485448 |
Jun 1995 |
US |
Child |
08926155 |
Sep 1997 |
US |
Parent |
08200235 |
Feb 1994 |
US |
Child |
08485448 |
Jun 1995 |
US |
Parent |
08023698 |
Feb 1993 |
US |
Child |
08200235 |
Feb 1994 |
US |
Parent |
08035150 |
Mar 1993 |
US |
Child |
08023698 |
Feb 1993 |
US |